Protego amyloidosis drug development receives $130M funding to target light chain amyloidosis, potentially improving treatment options.
Browsing: Clinical Trials & R&D
Latest clinical trial results, R&D progress, study updates, and global pharma research insights.
Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous setbacks.
Novo Nordisk GLP-1 drug fails to meet primary endpoints in Alzheimer’s trials, impacting neurodegeneration treatment hopes.
Bayer Asundexian trial results indicate potential for a new class of cardiovascular drugs in stroke prevention.
Novo Nordisk GLP-1 drug fails in Alzheimer’s trials, impacting potential neurodegeneration treatment.
Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.
Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.
Novo Nordisk GLP-1 trials did not meet primary endpoints in Alzheimer’s studies, impacting potential neurodegeneration treatment.
J&J Alzheimer’s trial failure with posdinemab dims hopes for new treatments.
Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.